Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Oligoprogressive 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 276pembrolizumab 227Magnetic Resonance Spectroscopy 226Carboplatin 180Cisplatin 166Biopsy 166Nivolumab 158Cyclophosphamide 144Radiotherapy 125Paclitaxel 124Gemcitabine 116Bevacizumab 95durvalumab 92Dexamethasone 88Rituximab 81Oxaliplatin 80venetoclax 75atezolizumab 71Fluorouracil 70Docetaxel 70Capecitabine 70Doxorubicin 68Etoposide 65Radiosurgery 64Ipilimumab 63Radiation 61Prednisone 60Cytarabine 60Lenalidomide 58Pemetrexed 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × DEAE-Dextran × 90 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

NCT07463248 2026-03-11

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

West China Hospital

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡